Raymond James raised the firm’s price target on HealthEquity to $95 from $90 and keeps an Outperform rating on the shares. The price target increase reflects HealthEquity’s leverage to elevated interest rates, which should benefit revenue growth through FY26, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HQY:
- HealthEquity Forum to Unveil 2024’s Top Employee Benefits Trends: AI, Cost Management, and More
- HealthEquity price target raised to $88 from $85 at Deutsche Bank
- HealthEquity price target raised to $93 from $89 at Wells Fargo
- HealthEquity sees FY25 revenue $1.14B-$1.16B, consensus $1.13B
- HealthEquity raises FY24 EPS view to $2.08-$2.16 from $1.97-$2.06
